



BRAINWORKS
The International Inflammatory
Brain Disease Outcome Study

Undefined Inflammatory Brain Disease Treatment Protocols

Last updated December 2014

BrainWorks IBrainD Protocol

Inflammatory brain disease, no brain biopsy

Low risk presentation - Treat for 3 months

Optional:

IV Methylprednisolone pulses


30mg/kg (max 1g)

x _____ days (3-7)

Prednisone daily

2 mg/kg (max 60 mg)

tapering biweekly**



** Example prednisone taper schedule: 60 mg/day, 50, 40, 30, 25, 20, 17.5, 15, 12.5, 10, 7.5, 5, 2.5, stop

BrainWorks IBrainD Protocol

Inflammatory brain disease, no brain biopsy

Intermediate risk presentation* - Treat for 6 months

Choose combination as clinically appropriate:

☐ **Steroids**

IV Methylprednisolone pulses

30mg/kg (max 1g)

x _____ days (3-7)

Start date _____

Prednisone PO daily

2 mg/kg (max 60 mg)

tapering monthly**

Start date _____

Dose _____ mg

Start date _____

Dose _____ mg

Start date _____

Dose _____ mg

Start date _____

Dose _____ mg

Start date _____

Dose _____ mg

Start date _____

Dose _____ mg

Start date _____

Dose _____ mg

☐ **IVIG** (2g/kg, max 70g)

Date _____

Dose _____ mg

Date _____

Dose _____ mg

Date _____

Dose _____ mg

Date _____

Dose _____ mg

Date _____

Dose _____ mg

Date _____

Dose _____ mg

☐ **Mycophenolate mofetil** (800-1200 mg/m² divided BID) Dose: _____

Stop date _____

or

☐ **Mycophenolic acid** (500-800 mg/m² divided BID) Dose: _____

Stop date _____

Calcium (1000 mg/day PO)

Vitamin D (1000 IU/day PO)



BRAINWORKS

The International Inflammatory
Brain Disease Outcome Study

* Intermediate risk defined as: patient presents with seizures/status epilepticus OR with functional deficits (i.e. Pediatric Stroke Outcome Measure [PSOM] score ≥ 1.0)

** Example prednisone taper schedule: 60 mg/day, 50, 40, 30, 25, 20, 17.5, 15, 12.5, 10, 7.5, 5, 2.5, stop

BrainWorks IBrainD Protocol

Inflammatory brain disease, no brain biopsy

High risk* - Phase 1: Induction Therapy (0 - 6 months)

IV Methylprednisolone pulses

30mg/kg (max 1g)

x _____ days (3-7)

Start date _____



BRAINWORKS

The International Inflammatory
Brain Disease Outcome Study

Prednisone PO daily

2 mg/kg (max 60 mg)

tapering monthly**

Start date _____

Dose _____ mg

Month 1

Start date _____

Dose _____ mg

Start date _____

Dose _____ mg

Start date _____

Dose _____ mg

Start date _____

Dose _____ mg

Start date _____

Dose _____ mg

Start date _____

Dose _____ mg

Cyclophosphamide (500-750 mg/m² monthly x 7 doses)

Date _____	Date _____	Date _____	Date _____	Date _____	Date _____	Date _____
Dose _____ mg	Dose _____ mg	Dose _____ mg	Dose _____ mg	Dose _____ mg	Dose _____ mg	Dose _____ mg

Trimethoprim/sulfamethoxazole (PJP prophylaxis dosing)

Calcium (1000 mg/day PO)

Vitamin D (1000 IU/day PO)

* High risk defined as brain biopsy positive disease

** Example prednisone taper schedule: 60 mg/day, 50, 40, 30, 25, 20, 17.5, 15, 12.5, 10, 7.5, 5, 2.5, stop

BrainWorks IBrainD Protocol

Inflammatory brain disease, no brain biopsy

High risk* - Phase 2: Maintenance Therapy (6 -18 months)




BRAINWORKS

The International Inflammatory
Brain Disease Outcome Study

Prednisone PO daily

Tapering monthly**

Start date _____



Choose:

Stop date _____

☐ **Mycophenolate mofetil** (800-1200 mg/m² divided BID) Dose: _____

Stop date _____

or

☐ **Mycophenolic acid** (500-800 mg/m² divided BID) Dose: _____

Stop date _____

or

☐ **Azathioprine** (2-3 mg/kg, max 150 mg, PO daily) Dose: _____

Stop date _____

Calcium (1000 mg/day PO)

Vitamin D (1000 IU/day PO)

* High risk defined as brain biopsy positive disease

** Example prednisone taper schedule: 60 mg/day, 50, 40, 30, 25, 20, 17.5, 15, 12.5, 10, 7.5, 5, 2.5, stop